References
- Alexander H, Nestle FO. Pathogenesis and immunotherapy in cutaneous psoriasis: What can rheumatologists learn? Curr Opin Rheumatol. . 2017; 29:71–78.
- Barot PA, Brahmbhatt NY, Malhotra SD, et al. Study of drug prescribing patterns in pasoriasis and assessment of rationality using sign and nice guidelines at a tertiary care teaching hospital. Int J Pharm Pharm Sci Res. 2016; 7:3073–3079.
- Rosa JF, Machado RF, Matias AT, et al. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J Eur Acad Dermatol. 2012; 26:348–353.
- Stinco G, Trevisan G, Piccirillo F, et al. Pruritus in chronic plaque psoriasis: a questionnaire-based study of 230 Italian patients. Acta Dermatovener Cr. 2014; 22:122–128.
- Xu T, Zhu Y, Wei Q, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008; 29:2126–2131.
- Nestle FO, Kaplan DH, Barker J, Mechanisms of D. Psoriasis. N Engl J Med. 2009; 361:496–509.
- Wang H, Syrovets T, Kess D, et al. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. Exp Dermatol. 2010; 19:175–175.